Filing Details

Accession Number:
0001140361-19-004808
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-12 20:19:21
Reporting Period:
2019-03-08
Accepted Time:
2019-03-12 20:19:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1121404 Sanofi 54 Rue La Boetie
Paris I0 75008
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-08 131,115 $412.17 20,723,717 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,799,552 Indirect See note
Footnotes
  1. Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D.
  2. Directly owned by Aventisub LLC ("Aventisub"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person.
  3. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.